<DOC>
	<DOC>NCT00108836</DOC>
	<brief_summary>This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Current doctor's diagnosis of generalized anxiety disorder In need of psychiatric treatment Willingness to complete all aspects of the study Current doctor's diagnosis of major depression History of schizophrenia or schizoaffective disorders Drug dependence within 2 months prior to study start For detailed information on eligibility, please contact the study center nearest to you (see below), or call 18627788300, or visit the following website: www.novartisclinicaltrials.com</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>GAD</keyword>
	<keyword>Anxiety</keyword>
	<keyword>XBD173</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
</DOC>